Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Carbapenem antibiotics Stories

2013-10-08 12:27:18

However, Hospital Pharmacy Directors Are Less Receptive to Formulary Inclusion Of Such Premium-Priced Antibiotics, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 8, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a majority of surveyed infectious disease (ID) specialists are willing to prescribe novel antibiotics, developed under the Infectious Diseases...

2013-08-29 08:25:23

Increased Use of Carbapenems and Colistin in Gram-Negative Infections Underscores the Urgent Need for New Antibiotics, According to a New Report from BioTrends Research Group and Arlington Medical Resources EXTON, Pa., Aug. 29, 2013 /PRNewswire/ -- BioTrends Research Group and Arlington Medical Resources find in their TreatmentTrends(®): Gram Negative Infections (US) 2013 report that infection rates due to drug-resistant Gram-negative (GN) pathogens are on the rise with over...

2013-07-19 14:38:41

Global structural properties have changed across bacterial families without putting limits on new antibiotic resistance Antibiotic-resistant bacteria have been emerging at an alarming rate. In some of the scariest of these pathogens, the mechanism responsible for the bacteria's ability to defeat antibiotics is a complex protein molecule embedded in the bacterial cell wall -- the enzyme β-lactamase. The rapid evolution of β-lactamase is the key factor responsible...

2013-06-12 08:29:45

EU5 Payers Indicate that Tightening Budgets Mean Emerging Brands Must Demonstrate Compelling Cost-Effectiveness Over Current Therapies in Order to Justify Reimbursement at a Premium Price, According to a New Report from Decision Resources BURLINGTON, Mass., June 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than half of surveyed physicians from the EU5 (France, Germany,...

2012-02-14 00:04:28

North Carolina State University chemists have created a compound that makes existing antibiotics 16 times more effective against recently discovered antibiotic-resistant “superbugs.” These so-called superbugs are actually bacterial strains that produce an enzyme known as New Delhi metallo-β-lactamase (NDM-1). Bacteria that produce this enzyme are practically impervious to antibiotics because NDM-1renders certain antibiotics unable to bind with their bacterial targets....

2011-11-16 11:20:00

LAKE FOREST, Ill., Nov. 16, 2011 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced the U.S. launch of imipenem-cilastatin for injection, I.V., the first generic version of this key antibiotic to become available in the United States. The medication, a carbapenem that belongs to the beta-lactam class of antibiotics, is a generic version of Merck's Primaxin®, which had 2010 U.S. sales of...

2010-06-23 06:16:00

VIENNA, Austria, June 23, 2010 /PRNewswire/ -- EUCODIS Bioscience, a developer and manufacturer of customized enzymes today announced that it has launched a high-performance beta-lactamase designed to inactivate a broad range of beta-lactam antibiotics. EUCODIS Bioscience is marketing the product under the LacBuster(TM) brand. Beta-lactamases are enzymes that inactivate beta-lactam antibiotics, hydrolyzing the beta-lactam ring, a molecular structure common to these drugs. This...

2010-06-22 10:29:00

LAKE FOREST, Ill., June 22 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced it has received U.S. Food and Drug Administration (FDA) approval for meropenem for injection, USP (I.V.) 500 mg and 1 g vials. The medication, a carbapenem that belongs to the beta-lactam class of antibiotics, is a generic version of AstraZeneca's Merrem® I.V. Sales of the name-brand product in the United States were...

2010-05-17 07:00:00

MALVERN, Pa., May 17 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that surveyed clinicians cite extended-spectrum beta-lactamase (ESBL)-producing E. coli and K. pneumoniae as the most concerning resistant pathogens in hospital-acquired gram-negative infections. These pathogens are resistant to commonly prescribed first-line antibiotics (e.g., penicillins, cephalosporins), and...

2010-03-15 11:10:00

SHENZHEN, CHINA, March 15 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) is pleased to announce that the Chilean government approved two of the company's penem injectables. Following 18 months of testing and negotiations, Chilean ISP (Ministry of Health) approved two of HTDS' penem injectables, Meropenem for Injection (MEINEN) and Imipenem for Injection (IMINEN). HTDS received the registration certificate for these two medications from the Chilean ISP and...